Research use only · EU-warehoused · COA on every batch · HPLC ≥99% · Shipment 2–5 days
Log in Register
Home/ Catalogue/ Neuroprotective/ P21 (P021)
In stock
P21 (P021)

P21 (P021)

Lyophilised · ≥99% (HPLC) ·

Quantity Volume discounts auto-applied
Custom quantity
1

Supplied lyophilised. Reconstitution typically uses bacteriostatic water.

Independently third-party tested · COA on every batch · 48h EU dispatch
[01]

Overview

P21 (P021) is a synthetic peptidomimetic cognitive enhancer (CAS 1246751-68-7; molecular formula C27H42N6O8; MW 578.7 g/mol) based on the acetylated Asp-Gly-Gly-Leu sequence conjugated to an adamantyl-amide group at the C-terminus (Ac-DGGL-AdNH2). It was designed to mimic the neurotrophic activity of CNTF (Ciliary Neurotrophic Factor) by targeting its receptor signalling axis, and has been studied in preclinical models of neurogenesis, synaptic plasticity, and age-related cognitive decline. Purity: HPLC ≥99%. For laboratory research use only; not for human or veterinary use.

Distilled from the active core of a natural nerve-growth factor into a fragment small enough to reach the brain, P21 (P021) is a synthetic neurotrophic peptide mimetic widely used in neurodegeneration research. It is an acetylated, adamantylated tetrapeptide (Ac-DGGL-Ψ(CH₂-NH)-AG) engineered from the biologically active region of human ciliary neurotrophic factor (CNTF), and has been studied across more than a decade of neurotrophic and cognitive-aging models.

A small molecule built from a large neurotrophin. Native neurotrophic proteins such as CNTF are powerful but impractical research tools: they are large, unstable, and cannot cross the blood-brain barrier. P021 was designed to overcome those limits by reproducing a short active motif of CNTF (residues 148–151), then adding an adamantane group and a reduced peptide bond to boost metabolic stability and lipophilicity. The result is a compact, orally stable peptidergic compound that researchers report enhances brain-derived neurotrophic factor (BDNF) expression and modulates leukemia-inhibitory-factor signalling — the mechanistic threads that run through most studies of the molecule.

What the research explores. Investigations in cellular and animal models have examined several dimensions of neurotrophic biology:

  • Neurogenesis and synaptic repair — work characterises peptide-driven neuroregeneration and synaptic plasticity as an emerging research modality (Kazim et al., 2016; Chohan et al., 2015).
  • Tau and amyloid pathology — studies report effects on tau-related and amyloid-β pathology in transgenic and aged-rodent models (Baazaoui et al., 2017; Khatoon et al., 2015).
  • Brain microstructure — diffusion-MRI work detects microstructural changes following early neurotrophic treatment in the 3xTg-AD model (Falangola et al., 2026).
  • Developmental neurotrophic timing — research examines outcomes when neurotrophic treatment is initiated during early postnatal development (Wei et al., 2021).

These results derive from in vitro and animal studies conducted in controlled research settings; they describe the compound's biology and do not constitute evidence of benefit for any non-investigational purpose. Full citations are listed under the Scientific References tab.

Physicochemical profile. CAS 1246751-68-7 · Molecular formula C₂₇H₄₂N₆O₈ · Molecular weight 578.7 · Sequence: Ac-DGGL-Ψ(CH₂-NH)-AG · Appearance: white lyophilized powder · Solubility: soluble in water.

Specification & quality. Each individually sealed vial contains 10 mg of P21 (P021) as a white lyophilized powder, verified at ≥99% purity by HPLC. Every batch is third-party tested, and a Certificate of Analysis (COA) is available. Store at −20 °C, protected from light and moisture.

This product is intended for laboratory research use only (RUO). It is not a drug, food, cosmetic, or dietary supplement, and is not for human or veterinary use, ingestion, or diagnostic application. Handling is restricted to qualified research professionals operating in an appropriately equipped laboratory.

Supplied for in-vitro laboratory research use only (RUO). Not a drug, food or supplement; not for human or veterinary use.

[04]

Quality & COA

Certificate of Analysis
Lot-specific COA with every order

Certificate of Analysis — lot-specific COA ships with every order and is available on request.

Each lot is tested by an independent third-party laboratory for identity (mass spectrometry) and purity (HPLC). The Certificate of Analysis for your specific batch ships with the order and is available on request — no house data, no exceptions.

HPLC purity
≥99% (HPLC)
Method
HPLC + MS
Endotoxin
Reported
[02]

Data Sheet

CAS number1246751-68-7
Molecular formulaC₂₇H₄₂N₆O₈
Molecular weight578.7
SequenceAc-DGGL-Ψ(CH₂-NH)-AG (BDNF-mimetic tetrapeptide)
Purity≥99% (HPLC)
Physical formWhite lyophilized powder
Quantity10mg/vial
SolubilitySoluble in water
StorageStore at -20°C, protect from light
Shelf life24 months from manufacture date
OriginEU · Slovakia
ClassificationResearch use only
[03]

Scientific References

01 Falangola MF, Voltin J, Cole M et al.. Corrigendum to Diffusion MRI measures detect brain microstructure changes due to early treatment with neurotrophic peptide mimetic P021 in the 3xTg-AD mouse model of Alzheimer's disease. Magn Reson Imaging. 2026 Jun;129:110641 Page: 9. Magn Reson Imaging. 2026. PMID: 41945082. doi:10.1016/j.mri.2026.110677. PubMed 02 Falangola MF, Voltin J, Cole M et al.. Diffusion MRI measures detect brain microstructure changes due to early treatment with neurotrophic peptide mimetic P021 in the 3xTg-AD mouse model of Alzheimer's disease. Magn Reson Imaging. 2026. PMID: 41740658. doi:10.1016/j.mri.2026.110641. PubMed 03 Mottolese N, Loi M, Trazzi S et al.. Effects of a ciliary neurotrophic factor (CNTF) small-molecule peptide mimetic in an in vitro and in vivo model of CDKL5 deficiency disorder. J Neurodev Disord. 2024. PMID: 39592934. doi:10.1186/s11689-024-09583-4. PubMed 04 Baazaoui N, Iqbal K. Alzheimer's Disease: Challenges and a Therapeutic Opportunity to Treat It with a Neurotrophic Compound. Biomolecules. 2022. PMID: 36291618. doi:10.3390/biom12101409. PubMed 05 Wei W, Liu Y, Dai CL et al.. Neurotrophic Treatment Initiated During Early Postnatal Development Prevents the Alzheimer-Like Behavior and Synaptic Dysfunction. J Alzheimers Dis. 2021. PMID: 34057082. doi:10.3233/JAD-201599. PubMed 06 Wei W, Wang Y, Liu Y et al.. Prenatal to early postnatal neurotrophic treatment prevents Alzheimer-like behavior and pathology in mice. Alzheimers Res Ther. 2020. PMID: 32854771. doi:10.1186/s13195-020-00666-7. PubMed 07 Liu Y, Wei W, Baazaoui N et al.. Inhibition of AMD-Like Pathology With a Neurotrophic Compound in Aged Rats and 3xTg-AD Mice. Front Aging Neurosci. 2019. PMID: 31803044. doi:10.3389/fnagi.2019.00309. PubMed 08 Baazaoui N, Iqbal K. Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound. Alzheimers Res Ther. 2017. PMID: 28655344. doi:10.1186/s13195-017-0273-7. PubMed 09 Kazim SF, Blanchard J, Bianchi R et al.. Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer's-like memory deficits in the Ts65Dn mouse model of Down syndrome. Sci Rep. 2017. PMID: 28368015. doi:10.1038/srep45561. PubMed 10 Baazaoui N, Iqbal K. Prevention of Amyloid-β and Tau Pathologies, Associated Neurodegeneration, and Cognitive Deficit by Early Treatment with a Neurotrophic Compound. J Alzheimers Dis. 2017. PMID: 28387677. doi:10.3233/JAD-170075. PubMed 11 Kazim SF, Iqbal K. Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's disease. Mol Neurodegener. 2016. PMID: 27400746. doi:10.1186/s13024-016-0119-y. PubMed 12 Chohan MO, Bragina O, Kazim SF et al.. Enhancement of neurogenesis and memory by a neurotrophic peptide in mild to moderate traumatic brain injury. Neurosurgery. 2015. PMID: 25255260. doi:10.1227/NEU.0000000000000577. PubMed 13 Khatoon S, Chalbot S, Bolognin S et al.. Elevated Tau Level in Aged Rat Cerebrospinal Fluid Reduced by Treatment with a Neurotrophic Compound. J Alzheimers Dis. 2015. PMID: 26401692. doi:10.3233/JAD-142799. PubMed 14 Kazim SF, Blanchard J, Dai CL et al.. Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease. Neurobiol Dis. 2014. PMID: 25046994. doi:10.1016/j.nbd.2014.07.001. PubMed 15 Bolognin S, Buffelli M, Puoliväli J et al.. Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound. Neurobiol Aging. 2014. PMID: 24702821. doi:10.1016/j.neurobiolaging.2014.02.017. PubMed

References are illustrative of the research literature surrounding this compound. All claims relate to in-vitro and animal models only.

[05]

FAQ

P21 (P021) is a synthetic neurotrophic peptide mimetic, a small peptide derived from the active core of a natural neurotrophic factor and widely used as a tool in neurodegeneration research. It is supplied for laboratory research use only (in vitro). It is not a medicine, food, supplement or medical device, and is not for human or veterinary use, administration or consumption.

P21 (P021) is a single, defined synthetic neurotrophic peptide mimetic with a known structure, whereas Cerebrolysin is a defined mixture of many short peptides and amino acids. One is a single characterised molecule; the other is a multi-component preparation. Both are studied in neuroprotection research and are supplied strictly for laboratory research use only (in vitro).

P21 (P021) is a synthetic neurotrophic peptide mimetic designed to mimic neurotrophic-factor activity, while Semax is a heptapeptide analogue of the ACTH(4-10) sequence. They originate from different biology and have distinct structures, so they serve as different research tools. Both are supplied as synthetic peptides for laboratory research use only and are not for human or veterinary use.

P21 (P021) is a neurotrophic peptide mimetic studied in neurodegeneration research, while Pinealon is a short tripeptide bioregulator studied in neuroprotective contexts. They differ in size, design and origin, making them distinct research reagents within the neuroprotective space. Both are offered strictly for laboratory research use only (in vitro), with no human or veterinary application.

P21 (P021) is a single, structurally defined peptide, which lets researchers work with one characterised molecule and control it as a single variable; Cerebrolysin is a multi-component mixture. The choice depends on whether a defined single compound or a complex preparation suits the study. Both are supplied strictly for laboratory research use only (in vitro), not for human or veterinary use.

P21 (P021) is a synthetic neurotrophic peptide mimetic studied in neurodegeneration research, while DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nonapeptide investigated in sleep and neuro contexts. They have different structures, origins and research focuses. Both are supplied as synthetic peptides for laboratory research use only and are not for human or veterinary use, administration or consumption.

Yes. Each batch is tested by an independent third-party laboratory, with identity confirmed by mass spectrometry and purity verified at ≥99% by HPLC, documented in a per-lot Certificate of Analysis. The product lists CAS 1246751-68-7 and molecular weight ~578.7 for reference. For detailed structural data, contact info@condorresearch.com. Supplied for laboratory research use only.

Yes. Every lot is tested by an independent third-party laboratory and ships with a per-batch Certificate of Analysis confirming identity by mass spectrometry and ≥99% purity by HPLC. Manufacturer documentation is not published, to preserve supply-chain integrity. To request the COA for a specific batch, contact info@condorresearch.com. P21 (P021) is supplied for laboratory research use only.

P21 (P021) is listed as soluble in water, so it is reconstituted with an aqueous diluent for analytical laboratory preparation; the vial contains 10 mg of lyophilised peptide. Store the unopened vial at -20°C, protected from light (24-month shelf life). Any reconstitution data is for in-vitro laboratory use only, never for human or animal use, and no dosing guidance is provided.

Yes. P21 (P021) is sold strictly for laboratory research use only (in vitro) and is explicitly not a medicine, food, supplement, cosmetic or medical device, and not for human or veterinary use, administration or consumption. All handling is laboratory preparation; no human or animal use guidance is provided. For further detail, contact info@condorresearch.com.

[06]

Reviews

Leave a review
Earn 250 points for a verified review (account required).
4.7
39 verified reviews
5
77%
4
15%
3
5%
2
3%
1
0%
Apr 2026
Exactly what research needs

No marketing fluff — just characterised material with paperwork. The data sheet and CAS matched our records precisely.

J. Meijer · Biotech R&D · NL Verified purchase
Mar 2026
High purity, clear labelling

Lyophilised cake was uniform and dissolved fully. Would appreciate a digital COA portal, but the PDF on request worked fine.

Dr. A. Bianchi · University · IT Verified purchase
Mar 2026
Trustworthy supplier

Identity by MS confirmed in our facility. Communication around storage and handling was precise and professional.

K. Wójcik · Research group · PL Verified purchase
Feb 2026
Reference-grade consistency

Reconstitution was clean with no visible particulates. The lot-specific COA matched the assay we ran in-house — purity is exactly as stated.

Dr. M. Hartmann · Research lab · DE Verified purchase
Jan 2026
COA matched our own HPLC

We verify every incoming compound by HPLC; this batch came back within tolerance of the certificate. Dispatch from the EU warehouse was quick.

L. Fischer · University group · AT Verified purchase

Related compounds